DrugPatentWatch Database Preview
Drugs in Development Information for Fasudil
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Fasudil?
Fasudil is an investigational drug.
There have been 10 clinical trials for Fasudil.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2019.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Heart Failure. The leading clinical trial sponsors are Shahid Beheshti University of Medical Sciences, Brigham and Women's Hospital, and Colorado State University.
There are eight hundred and forty-one US patents protecting this investigational drug and eight international patents.
Summary for Fasudil
| US Patents | 841 |
| International Patents | 8,881 |
| US Patent Applications | 1,709 |
| WIPO Patent Applications | 1,294 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2019-07-01) |
| Vendors | 55 |
Recent Clinical Trials for Fasudil
| Title | Sponsor | Phase |
|---|---|---|
| Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction | RenJi Hospital | Phase 4 |
| Fasudil Eye Drop in Retinopathy Of Prematurity(ROP) | Shahid Beheshti University of Medical Sciences | Phase 2/Phase 3 |
| Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS | University Medical Center Goettingen | Phase 2 |
Clinical Trial Summary for Fasudil
Top disease conditions for Fasudil
Top clinical trial sponsors for Fasudil
US Patents for Fasudil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fasudil | Start Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| Fasudil | Start Trial | Use of anthelmintic agents against Dirofilaria immitis | Intervet Inc. (Madison, NJ) | Start Trial |
| Fasudil | Start Trial | Diarylimidazole compound and harmful organism control agent | Nippon Soda Co., Ltd. (Tokyo, JP) | Start Trial |
| Fasudil | Start Trial | Minimal volume reprogramming of mononuclear cells | Fate Therapeutics, Inc. (San Diego, CA) | Start Trial |
| Fasudil | Start Trial | Alkynyl pyridine-substituted amide compound and pesticide | Nissan Chemical Industries, Ltd. (Chiyoda-ku, JP) | Start Trial |
| Fasudil | Start Trial | Corneal thickness modulating agent | KOWA COMPANY, LTD. (Nagoya-shi, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fasudil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fasudil | European Patent Office | 2981556 | 2033-04-02 | Start Trial |
| Fasudil | World Intellectual Property Organization (WIPO) | 2014165513 | 2033-04-02 | Start Trial |
| Fasudil | Australia | 2015286634 | 2034-07-11 | Start Trial |
| Fasudil | Brazil | 112017000398 | 2034-07-11 | Start Trial |
| Fasudil | China | 106659720 | 2034-07-11 | Start Trial |
| Fasudil | European Patent Office | 3177291 | 2034-07-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
